Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Kangzhe Pharmaceutical: New drug Desidustat tablets for renal anemia approved for market launch in China
People’s Financial News, March 13 — Kangzhe Pharmaceutical Holdings Limited (referred to as “Kangzhe Pharma”) announced that the new drug for renal anemia, Dextudose tablets (originally named Deduose tablets), received approval from the China National Medical Products Administration (NMPA) on March 13, 2026, for its marketing application. This product is an innovative oral hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI), suitable for the treatment of anemia in non-dialysis adult patients with chronic kidney disease (CKD).